US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OS Therapies

1.55

-0.0400-2.52%

Post-market: 1.560.0100+0.65%19:30 EDT

Volume:438.88K

Turnover:663.36K

Market Cap:71.49M

PE:-1.47

High:1.55

Open:1.50

Low:1.46

Close:1.59

52wk High:2.54

52wk Low:1.15

Shares:46.13M

Float Shares:33.71M

Volume Ratio:0.91

T/O Rate:1.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0524

EPS(LYR):-0.9829

ROE:-914.04%

ROA:-232.65%

PB:-6.00

PE(LYR):-1.58

Loading ...

Overview Company News Filings

OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street

OS Therapies Gains EMA Rolling Review for OST-HER2

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies says EMA starts rolling review for OST-HER2 conditional approval application

OS Therapies files patent application for Listeria immune-response biomarker signature

OS Therapies reports Phase 2b biomarker signature tied to OST-HER2 survival outcomes

OS Therapies appoints Moderna co-founder Robert Langer as strategic advisor

OS Therapies appoints Guardant Health CMO Craig Eagle to strategic advisory board

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies bolsters funding to advance OST-HER2 program

OS Therapies completes USD 5.25 million registered direct offering

OS Therapies Files Prospectus Supplement for Share Resale

OS Therapies FY25 net loss widens to $28.8 million

OS Therapies files prospectus supplement for resale of up to 10.53 million shares

Os Therapies - Files to Register 10.5 Mln Shares for Resale by Selling Stockholders - SEC Filing

THOMSON REUTERS

OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate

Benzinga Earnings

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies granted meetings with FDA, MHRA, EMA and TGA; Phase 3 enrollment expected to begin in Q3 FY2026 in Australia

OS Therapies rises; EMA grants ATMP designation for OST-HER2 in resected osteosarcoma pulmonary recurrence

OS Therapies Is Maintained at Buy by D. Boral Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/OSTX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.55,"timestamp":1787601600000,"preClose":1.59,"halted":0,"volume":438883,"hourTrading":{"tag":"盘后","latestPrice":1.56,"preClose":1.55,"latestTime":"19:30 EDT","volume":645,"amount":1001.4055,"timestamp":1787614207063,"change":0.01,"changeRate":0.006452,"amplitude":0.012903},"delay":0,"changeRate":-0.025157232704402538,"floatShares":33708100,"shares":46125800,"eps":-1.05241,"marketStatus":"Closed","change":-0.04,"latestTime":"08-24 16:00:00 EDT","open":1.5,"high":1.55,"low":1.4602,"amount":663364.7640369,"amplitude":0.056478,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.05241,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.59,"preHourTrading":{"tag":"盘前","latestPrice":1.51,"preClose":1.59,"latestTime":"09:25 EDT","volume":13687,"amount":20358.919768,"timestamp":1787577918670,"change":-0.08,"changeRate":-0.050314,"amplitude":0.075472},"postHourTrading":{"tag":"盘后","latestPrice":1.56,"preClose":1.55,"latestTime":"19:30 EDT","volume":645,"amount":1001.4055,"timestamp":1787614207063,"change":0.01,"changeRate":0.006452,"amplitude":0.012903},"volumeRatio":0.905397},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":33708100,"roa":"-232.65%","roe":"-914.04%","lyrEps":-0.982926,"volumeRatio":0.905397,"shares":46125800,"dividePrice":0,"high":1.55,"amplitude":0.056478,"preClose":1.59,"low":1.4602,"week52Low":1.15,"pbRate":"-6.00","week52High":2.5365,"institutionHeld":0,"latestPrice":1.55,"eps":-1.05241,"divideRate":0,"volume":438883,"delay":0,"ttmEps":-1.05241,"open":1.5,"prevYearClose":1.4,"prevWeekClose":1.59,"prevMonthClose":1.52,"prevQuarterClose":1.9,"fiveDayClose":1.47,"twentyDayClose":1.53,"sixtyDayClose":1.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1783828800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2026-08-21","current":-1.47281,"percent":0.994208,"low":-14.897496,"twenty":-8.123117,"median":-4.411096,"eighty":-2.573055,"high":-1.629046,"avg":-5.20719,"sd":3.23803,"marketCap":70370207},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762},{"date":"2025-06-20","current":-4.525147,"twenty":-11.288606,"median":-6.448552,"eighty":-4.525147,"marketCap":51137808},{"date":"2025-06-27","current":-4.500284,"twenty":-11.257432,"median":-6.245836,"eighty":-4.450557,"marketCap":50856831},{"date":"2025-07-03","current":-4.804944,"twenty":-11.153916,"median":-6.178419,"eighty":-4.480042,"marketCap":54299732},{"date":"2025-07-11","current":-4.384839,"twenty":-11.071717,"median":-6.001438,"eighty":-4.444649,"marketCap":49552214},{"date":"2025-07-18","current":-4.411096,"twenty":-11.057637,"median":-5.848373,"eighty":-4.413618,"marketCap":49848934},{"date":"2025-07-25","current":-5.118748,"twenty":-11.006503,"median":-5.726085,"eighty":-4.413618,"marketCap":57845975},{"date":"2025-08-01","current":-5.266689,"twenty":-10.886225,"median":-5.658739,"eighty":-4.423405,"marketCap":59517824},{"date":"2025-08-08","current":-5.177924,"twenty":-10.817778,"median":-5.632611,"eighty":-4.43502,"marketCap":58514715},{"date":"2025-08-15","current":-6.36145,"twenty":-10.649839,"median":-5.600996,"eighty":-4.43838,"marketCap":71889507},{"date":"2025-08-22","current":-5.360009,"twenty":-10.610453,"median":-5.567348,"eighty":-4.444649,"marketCap":76540639},{"date":"2025-08-29","current":-5.047341,"twenty":-10.610453,"median":-5.538676,"eighty":-4.449676,"marketCap":72075768},{"date":"2025-09-05","current":-4.667674,"twenty":-10.601601,"median":-5.456641,"eighty":-4.458388,"marketCap":66654139},{"date":"2025-09-12","current":-5.119065,"twenty":-10.582903,"median":-5.4212,"eighty":-4.477891,"marketCap":73099984},{"date":"2025-09-19","current":-4.897461,"twenty":-10.460155,"median":-5.370028,"eighty":-4.495136,"marketCap":69935483},{"date":"2025-09-26","current":-4.675856,"twenty":-10.329392,"median":-5.362697,"eighty":-4.515202,"marketCap":66770981},{"date":"2025-10-03","current":-4.409931,"twenty":-10.231142,"median":-5.325865,"eighty":-4.459866,"marketCap":62973579},{"date":"2025-10-10","current":-4.520733,"twenty":-10.170508,"median":-5.292169,"eighty":-4.471291,"marketCap":64555830},{"date":"2025-10-17","current":-4.099684,"twenty":-10.138159,"median":-5.266689,"eighty":-4.443146,"marketCap":58543277},{"date":"2025-10-24","current":-4.250282,"twenty":-10.078376,"median":-5.177924,"eighty":-4.421116,"marketCap":60693806},{"date":"2025-10-31","current":-4.156353,"twenty":-9.977535,"median":-5.177924,"eighty":-4.412988,"marketCap":59352507},{"date":"2025-11-07","current":-4.273765,"twenty":-9.834079,"median":-5.118748,"eighty":-4.402429,"marketCap":61029131},{"date":"2025-11-14","current":-4.273765,"twenty":-9.766275,"median":-5.104544,"eighty":-4.391176,"marketCap":61029131},{"date":"2025-11-21","current":-2.971008,"twenty":-9.761488,"median":-5.059977,"eighty":-4.38129,"marketCap":54322633},{"date":"2025-11-28","current":-3.447432,"twenty":-9.750618,"median":-5.0362,"eighty":-4.358965,"marketCap":63033690},{"date":"2025-12-05","current":-3.50521,"twenty":-9.73315,"median":-4.994703,"eighty":-4.321289,"marketCap":64090120},{"date":"2025-12-12","current":-3.909657,"twenty":-9.718269,"median":-4.969558,"eighty":-4.300776,"marketCap":71485134},{"date":"2025-12-19","current":-3.081503,"twenty":-9.704683,"median":-4.950787,"eighty":-4.273765,"marketCap":56342963},{"date":"2025-12-26","current":-2.927428,"twenty":-9.698213,"median":-4.936226,"eighty":-4.231496,"marketCap":53525815},{"date":"2026-01-02","current":-2.696315,"twenty":-9.672334,"median":-4.919621,"eighty":-4.226786,"marketCap":49300092},{"date":"2026-01-09","current":-2.965947,"twenty":-9.672334,"median":-4.910716,"eighty":-4.157441,"marketCap":54230102},{"date":"2026-01-16","current":-2.811872,"twenty":-9.575287,"median":-4.897871,"eighty":-4.145979,"marketCap":51412953},{"date":"2026-01-23","current":-2.831131,"twenty":-9.549408,"median":-4.897461,"eighty":-4.087363,"marketCap":51765097},{"date":"2026-01-30","current":-2.657797,"twenty":-9.439422,"median":-4.891008,"eighty":-3.973179,"marketCap":48595805},{"date":"2026-02-06","current":-2.445943,"twenty":-9.413543,"median":-4.875301,"eighty":-3.908145,"marketCap":44722227},{"date":"2026-02-13","current":-2.23409,"twenty":-9.413543,"median":-4.874269,"eighty":-3.823969,"marketCap":40848648},{"date":"2026-02-20","current":-2.311128,"twenty":-9.35512,"median":-4.850347,"eighty":-3.774842,"marketCap":42257222},{"date":"2026-02-27","current":-2.754094,"twenty":-9.300118,"median":-4.8312,"eighty":-3.691488,"marketCap":50356523},{"date":"2026-03-06","current":-2.908169,"twenty":-9.286254,"median":-4.804944,"eighty":-3.509217,"marketCap":53173671},{"date":"2026-03-13","current":-2.927428,"twenty":-9.264738,"median":-4.804459,"eighty":-3.458987,"marketCap":53525815},{"date":"2026-03-20","current":-2.888909,"twenty":-9.232389,"median":-4.792605,"eighty":-3.347283,"marketCap":52821528},{"date":"2026-03-27","current":-2.638537,"twenty":-9.139288,"median":-4.763734,"eighty":-3.283217,"marketCap":48243662},{"date":"2026-04-02","current":-1.869843,"twenty":-9.07459,"median":-4.734863,"eighty":-3.19573,"marketCap":53765188},{"date":"2026-04-10","current":-1.973708,"twenty":-9.037738,"median":-4.706449,"eighty":-3.15544,"marketCap":56751705},{"date":"2026-04-17","current":-2.046809,"twenty":-9.001875,"median":-4.699192,"eighty":-3.081503,"marketCap":58853620},{"date":"2026-04-24","current":-2.119909,"twenty":-8.908899,"median":-4.683564,"eighty":-3.034837,"marketCap":60955535},{"date":"2026-05-01","current":-2.485411,"twenty":-8.768822,"median":-4.677121,"eighty":-2.985206,"marketCap":71465110},{"date":"2026-05-08","current":-2.485411,"twenty":-8.7364,"median":-4.657962,"eighty":-2.965947,"marketCap":71465110},{"date":"2026-05-15","current":-2.748572,"twenty":-8.699253,"median":-4.619378,"eighty":-2.954392,"marketCap":79032004},{"date":"2026-05-22","current":-2.169023,"twenty":-8.649859,"median":-4.610947,"eighty":-2.927428,"marketCap":76509706},{"date":"2026-05-29","current":-2.500026,"twenty":-8.617798,"median":-4.590507,"eighty":-2.912021,"marketCap":88185449},{"date":"2026-06-05","current":-2.335883,"twenty":-8.605027,"median":-4.574874,"eighty":-2.888909,"marketCap":82395496},{"date":"2026-06-12","current":-2.159113,"twenty":-8.590585,"median":-4.542637,"eighty":-2.850391,"marketCap":76160161},{"date":"2026-06-18","current":-2.17174,"twenty":-8.57247,"median":-4.525147,"eighty":-2.831131,"marketCap":76605542},{"date":"2026-06-26","current":-2.272751,"twenty":-8.516979,"median":-4.520733,"eighty":-2.811872,"marketCap":80168590},{"date":"2026-07-02","current":-2.285377,"twenty":-8.509613,"median":-4.508587,"eighty":-2.790024,"marketCap":80613971},{"date":"2026-07-10","current":-2.17174,"twenty":-8.507772,"median":-4.481912,"eighty":-2.769501,"marketCap":76605542},{"date":"2026-07-17","current":-1.893959,"twenty":-8.481893,"median":-4.461622,"eighty":-2.745824,"marketCap":66807159},{"date":"2026-07-24","current":-1.969717,"twenty":-8.439377,"median":-4.448354,"eighty":-2.715575,"marketCap":69479445},{"date":"2026-07-31","current":-1.969717,"twenty":-8.312777,"median":-4.438389,"eighty":-2.696315,"marketCap":69479445},{"date":"2026-08-07","current":-2.058102,"twenty":-8.184914,"median":-4.437352,"eighty":-2.657797,"marketCap":72597112},{"date":"2026-08-14","current":-2.020223,"twenty":-8.139646,"median":-4.419971,"eighty":-2.618363,"marketCap":71260969},{"date":"2026-08-21","current":-1.787426,"twenty":-8.123117,"median":-4.411096,"eighty":-2.573055,"marketCap":70370207}],"updateTime":1787617884374},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2632643704","title":"OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2632643704","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632643704?lang=en_us&edition=fundamental","pubTime":"2026-05-01 23:35","pubTimestamp":1777649750,"startTime":"0","endTime":"0","summary":"In a report released today, Chad Messer from Lake Street maintained a Buy rating on OS Therapies Incorporated, with a price target of $14.00. Messe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/os-therapies-incorporated-ostx-gets-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/os-therapies-incorporated-ostx-gets-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632664219","title":"OS Therapies Gains EMA Rolling Review for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2632664219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632664219?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:18","pubTimestamp":1777583885,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) has issued an announcement. On April 30, 2026, OS Therapies announced that the European Medicines Agency has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081","OST","BK4139","BK4148","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631320466","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2631320466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631320466?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:33","pubTimestamp":1777552380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 08:33 ET (12:33 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631870086","title":"OS Therapies says EMA starts rolling review for OST-HER2 conditional approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2631870086","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631870086?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:20","pubTimestamp":1777544430,"startTime":"0","endTime":"0","summary":"EMA started rolling review of OST-HER2 conditional marketing authorization filing from OS Therapies for prevention or delay of recurrence in fully resected pulmonary metastatic osteosarcoma.Review will be completed using 3-year overall survival data, with OS Therapies targeting an EMA decision in Q4 2026.Australia TGA invited a provisional determination application, with a rolling review decision expected after a Phase 3 clinical trial notification later in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL1NN0fY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627297982","title":"OS Therapies files patent application for Listeria immune-response biomarker signature","url":"https://stock-news.laohu8.com/highlight/detail?id=2627297982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627297982?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:37","pubTimestamp":1776339467,"startTime":"0","endTime":"0","summary":"OS Therapies filed patent application covering biomarkers tied to immune response to its Listeria monocytogenes platform.Filing targets treatment-emergent immune signature linked to downregulation of tumor immune-evasion genes.Application also covers upregulation of genes associated with cytotoxic cellular immune activation.Biomarker signature was identified using data from Phase 2b trial of OST-HER2 in fully resected pulmonary metastatic osteosarcoma.OS Therapies plans conference call later in April 2026 to review biomarker signature data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL9fcgtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627729244","title":"OS Therapies reports Phase 2b biomarker signature tied to OST-HER2 survival outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2627729244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627729244?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:21","pubTimestamp":1776338460,"startTime":"0","endTime":"0","summary":"OS Therapies filed a new patent application covering a treatment-emergent immune biomarker signature tied to response in its Phase 2b trial of OST-HER2 in resected pulmonary metastatic osteosarcoma.Biomarker findings were not yet presented; management plans a conference call later in April 2026 to review the signature and its link to clinical outcomes.Company reported that patients showing the signature were the ones who achieved longer-term survival outcomes, supporting its strategy to use the biomarker as a surrogate endpoint in regulatory filings.OS Therapies targets a Biologics License Application under FDA Accelerated Approval in second half of 2026, positioning the biomarker as decision-driving evidence for earlier market access.Priority Review Voucher economics remain central to upside case, with most recent disclosed transaction in February 2026 valued at USD 205 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL379nG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627431812","title":"OS Therapies appoints Moderna co-founder Robert Langer as strategic advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2627431812","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627431812?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:02","pubTimestamp":1776074546,"startTime":"0","endTime":"0","summary":"OS Therapies appointed Robert “Bob” S. Langer to its strategic advisory board.Langer is an MIT Institute Professor who co-founded Moderna.He will advise on prioritizing OS Therapies’ listeria-oncology pipeline.Mandate includes evaluating combinations with other oncology technologies.Scope also covers selection of tunable antibody-drug conjugate candidates for further development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4ywHk8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4585","BK4551","BK4588","BK4139","BK4532","BK4548","MRNA","BK4534","BK4501","MRNX","BK4533","BK4568","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625287579","title":"OS Therapies appoints Guardant Health CMO Craig Eagle to strategic advisory board","url":"https://stock-news.laohu8.com/highlight/detail?id=2625287579","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625287579?lang=en_us&edition=fundamental","pubTime":"2026-04-08 23:39","pubTimestamp":1775662754,"startTime":"0","endTime":"0","summary":"OS Therapies appointed Craig Eagle, MD to newly formed strategic advisory board on April 8, 2026.Mandate includes pipeline prioritization beyond osteosarcoma as company advances clinical-stage oncology programs.Eagle is Chief Medical Officer at Guardant Health.Career background includes senior oncology leadership roles at Genentech, Pfizer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9HT053:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","LU0225284248.USD","LU1883839398.USD","LU1057294990.SGD","SG9999013999.USD","GH","IE00B19Z3581.USD","LU0456855351.SGD","LU0868494617.USD","SG9999003800.SGD","BK4581","SG9999011175.SGD","BK4535","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU1066053197.SGD","LU0225771236.USD","LU0985481810.HKD","BK4550","LU1894683264.USD","BK4534","LU0321505439.SGD","BK4551","SGXZ57979304.SGD","IE0002270589.USD","LU1894683348.USD","SG9999001176.SGD","OSTX","BK4196","BK4139","IE00BBT3K403.USD","BK4533","IE00BLSP4239.USD","LU0170899867.USD","BK4592","LU0306807586.USD","BK4599","LU0058720904.USD","LU0234572021.USD","BK4568","BK4588","LU1023059063.AUD","SG9999001176.USD","BK4585","IE000M9KFDE8.USD","BK4007","SG9999002232.USD","LU0122379950.USD","LU0306806265.USD","SG9999002224.SGD","LU0289739699.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625794607","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2625794607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625794607?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:14","pubTimestamp":1775650440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 08:14 ET (12:14 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624638977","title":"OS Therapies bolsters funding to advance OST-HER2 program","url":"https://stock-news.laohu8.com/highlight/detail?id=2624638977","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624638977?lang=en_us&edition=fundamental","pubTime":"2026-04-03 06:40","pubTimestamp":1775169600,"startTime":"0","endTime":"0","summary":"An update from OS Therapies Incorporated ( ($OSTX) ) is now available. On March 31, 2026, OS Therapies entered into a securities purchase agreement...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-bolsters-funding-to-advance-ost-her2-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-bolsters-funding-to-advance-ost-her2-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OST","BK4148","OS","OSTX","BK4139","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624766687","title":"OS Therapies completes USD 5.25 million registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2624766687","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624766687?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:15","pubTimestamp":1775164555,"startTime":"0","endTime":"0","summary":"OS Therapies completed a registered direct follow-on offering raising USD 5.25 million from primarily pre-existing high-net-worth investors.Deal priced at USD 1.40 per share, or USD 1.399 per pre-funded warrant.Investors also received warrants exercisable at USD 1.40 per share.Company expects about USD 2 million in VAT refunds in 2Q-26 from its U.K. subsidiary.Management forecasts about USD 2 million in U.K. R&D tax credits in 2H-26, extending cash runway into 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL4BmSv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624552529","title":"OS Therapies Files Prospectus Supplement for Share Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2624552529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624552529?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:07","pubTimestamp":1775002053,"startTime":"0","endTime":"0","summary":"The latest update is out from OS Therapies Incorporated ( ($OSTX) ). On March 31, 2026, OS Therapies Incorporated filed a prospectus supplement wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-supplement-for-share-resale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-supplement-for-share-resale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OSTX","BK4139","OS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624558418","title":"OS Therapies FY25 net loss widens to $28.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624558418","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624558418?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:59","pubTimestamp":1774990776,"startTime":"0","endTime":"0","summary":"OS Therapies posted a net loss of USD 29 million for fiscal 2025.Research and development expense climbed to USD 16 million, due to higher vendor costs tied to FDA approval efforts and regulatory submissions for OST-HER2.General and administrative expense increased to USD 12 million on higher marketing and investor relations costs, advisory fees, and legal fees tied to PIPE financing and a terminated equity line.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4MqC2z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530301","title":"OS Therapies files prospectus supplement for resale of up to 10.53 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530301","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530301?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:22","pubTimestamp":1774988579,"startTime":"0","endTime":"0","summary":"OS Therapies filed a prospectus supplement covering resale of up to 10,529,417 common shares by selling stockholders.Prospectus supplement forms part of company Form S-3 registration statement  declared effective Aug. 12, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL2NchNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624553743","title":"Os Therapies - Files to Register 10.5 Mln Shares for Resale by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624553743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624553743?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:11","pubTimestamp":1774987864,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1OD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623869475","title":"OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623869475","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623869475?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:54","pubTimestamp":1774958099,"startTime":"0","endTime":"0","summary":"OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.13) by 228 percent. This is a 70.83 percent decrease over losses of $(0.24) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51563471/os-therapies-q4-eps-0-41-misses-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622387211","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2622387211","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622387211?lang=en_us&edition=fundamental","pubTime":"2026-03-28 02:27","pubTimestamp":1774636020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 14:27 ET (18:27 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622840871","title":"OS Therapies granted meetings with FDA, MHRA, EMA and TGA; Phase 3 enrollment expected to begin in Q3 FY2026 in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2622840871","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622840871?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:14","pubTimestamp":1774606476,"startTime":"0","endTime":"0","summary":"OS Therapies said it was granted meetings with the FDA, MHRA, EMA, and TGA to review the proposed global confirmatory Phase 3 trial design for OST-HER2 in metastatic osteosarcoma.The company said the meetings are expected to occur in Q2 2026, and trial enrollment is expected to begin in Q3 2026 initially in Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2SjXMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024928","title":"OS Therapies rises; EMA grants ATMP designation for OST-HER2 in resected osteosarcoma pulmonary recurrence","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024928","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024928?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:01","pubTimestamp":1774432873,"startTime":"0","endTime":"0","summary":"European Medicines Agency’s Committee for Advanced Therapies granted Advanced Therapy Medicinal Product designation to OS Therapies’ OST-HER2 for pulmonary recurrence in resected osteosarcoma in the EU.OS Therapies said it is finalizing a Conditional Marketing Authorisation submission to the EMA for OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma.Paul Romness said the company expects to deliver regulatory dossiers to the EMA, the U.K. Medicines and Healthcare products Regulatory Agency, and the U.S. Food and Drug Administration in the coming weeks.A recent publicly disclosed Priority Review Voucher transaction was reported at $205 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL5hhjkT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618679567","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618679567","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618679567?lang=en_us&edition=fundamental","pubTime":"2026-03-10 02:52","pubTimestamp":1773082320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 14:52 ET (18:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":63,"code":"91000000","status":"200"}]}}